ClinicalTrials.gg
RecruitingNCT06767683Updated Oct 9, 2026

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

A Phase 2/3 interventional study of ALKS 2680, 4mg and ALKS 2680, 6mg in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia, sponsored by Alkermes, Inc.. Recruiting at 50 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Alkermes, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 9, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
786
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
Largest of 27
786 · median 100
Started
2025
with 4 others
Phase 2/3
2 of 30
2 open now
Primary completion
2030-06
later than 9 of 12 live
Registered
23rd of 30
by date
Lead sponsor
2 of 30
Alkermes, Inc.

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one has the largest planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 9 of the 12 other live ones, and was the 23rd registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.

03

Conditions studied

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Keywords

  • Narcolepsy
  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • NT1
  • NT2
  • orexin-2 receptor agonist
  • sleep
  • sleep disorder
  • excessive daytime sleepiness
  • IH
  • Idiopathic Hypersomnia
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1)
  • Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects)

Exclusion criteria

Exclusion Criteria:

  • Developed a new health condition, or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study
  • Is currently pregnant, breastfeeding, or planning to become pregnant during the study
  • Is currently enrolled in another clinical study (other than the parent study) or used any drug or device within 30 days prior to Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
786 participants (estimated)

Study arms

  • Experimental
    Narcolepsy Type 1 (NT1)

    Drug: ALKS 2680, 4mg · Drug: ALKS 2680, 6mg · Drug: ALKS 2680, 8mg

  • Experimental
    Narcolepsy Type 2 (NT2)

    Drug: ALKS 2680, 10mg · Drug: ALKS 2680, 14mg · Drug: ALKS 2680, 18mg

  • Experimental
    Idiopathic Hypersomnia (IH)

    Drug: ALKS 2680, 10mg · Drug: ALKS 2680, 14mg · Drug: ALKS 2680, 18mg

Interventions

  • Oral tablet containing 4 mg of ALKS 2680 for once daily administration

  • Oral tablet containing 6 mg of ALKS 2680 for once daily administration

  • Oral tablet containing 8 mg of ALKS 2680 for once daily administration

  • Oral tablet containing 10 mg of ALKS 2680 for once daily administration

  • Oral tablet containing 14 mg of ALKS 2680 for once daily administration

  • Oral tablet containing 18 mg of ALKS 2680 for once daily administration

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: Up to 248 Weeks

Secondary outcomes

  1. Change in the mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT)

    Time frame: Baseline to Week 24

  2. Change in Epworth Sleepiness Scale (ESS)

    Time frame: Baseline to up to week 240

  3. Change in weekly cataplexy rate (WCR)

    Time frame: Baseline up to week 240

  4. Change in Idiopathic Hypersomnia Severity Scale (IHSS)

    Only applicable for IH participants

    Time frame: Baseline up to week 240

07

Study locations

50 of 50 sites recruiting
  • Alkermes Investigational Site
    Cullman, Alabama 35055, United States
    Recruiting
  • Alkermes Investigator Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Alkermes Investigational Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Alkermes Investigational Site
    Los Angeles, California 90025, United States
    Recruiting
  • Alkermes Investigator Site
    San Francisco, California 94158, United States
    Recruiting
  • Alkermes Investigational Site
    Stanford, California 94305, United States
    Recruiting
  • Alkermes Investigational Site
    Boulder, Colorado 80309, United States
    Recruiting
  • Alkermes Investigational Site
    Colorado Springs, Colorado 80918, United States
    Recruiting
  • Alkermes Investigational Site
    Brandon, Florida 33511, United States
    Recruiting
  • Alkermes Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • Alkermes Investigational Site
    Winter Park, Florida 32789, United States
    Recruiting
  • Alkermes Investigational Site
    Atlanta, Georgia 30328, United States
    Recruiting
  • Alkermes Investigational Site
    Macon, Georgia 31210, United States
    Recruiting
  • Alkermes Investigational Site
    Stockbridge, Georgia 30281, United States
    Recruiting
  • Alkermes Investigational Site
    Peoria, Illinois 61637, United States
    Recruiting
  • Alkermes Investigational Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Alkermes Investigational Site
    Lansing, Michigan 48911, United States
    Recruiting
  • Alkermes Investigational Site
    Sterling Heights, Michigan 48314, United States
    Recruiting
  • Alkermes Investigational Site
    Lincoln, Nebraska 68506, United States
    Recruiting
  • Alkermes Investigational Site
    Middletown, New Jersey 07748, United States
    Recruiting
  • Alkermes Investigational Site
    Denver, North Carolina 28037, United States
    Recruiting
  • Alkermes Investigational Site
    Huntersville, North Carolina 28708, United States
    Recruiting
  • Alkermes Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • Alkermes Investigational Site
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Alkermes Investigational Site
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Alkermes Investigational Site
    Dublin, Ohio 43017, United States
    Recruiting
  • Alkermes Investigational Site
    Abington, Pennsylvania 19001, United States
    Recruiting
  • Alkermes Investigational Site
    Wyomissing, Pennsylvania 19610, United States
    Recruiting
  • Alkermes Investigational Site
    Columbia, South Carolina 29201, United States
    Recruiting
  • Alkermes Investigational Site
    Austin, Texas 78731, United States
    Recruiting
  • Alkermes Investigational Site
    Dallas, Texas 75251, United States
    Recruiting
  • Alkermes Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Alkermes Investigational Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Alkermes Investigational Site
    Madison, Wisconsin 53706, United States
    Recruiting
  • Alkermes Investigational Site
    Sydney, New South Wales 2113, Australia
    Recruiting
  • Alkermes Investigational Site
    Bedford Park, South Australia 5042, Australia
    Recruiting
  • Alkermes Investigational Site
    Clayton, Victoria 3168, Australia
    Recruiting
  • Alkermes Investigational Site
    Bruges, Brugge 8000, Belgium
    Recruiting
  • Alkermes Investigational Site
    Alken, 3570, Belgium
    Recruiting
  • Alkermes Investigational Site
    Namur, 5101, Belgium
    Recruiting
  • Alkermes Investigational Site
    Prague, 128 21, Czechia
    Recruiting
  • Alkermes Investigational Site
    Montpellier, Herault 34295, France
    Recruiting
  • Alkermes Investigational Site
    Bordeaux, 33000, France
    Recruiting
  • Alkermes Investigational Site
    Bologna, 40139, Italy
    Recruiting
  • Alkermes Investigational Site
    Milan, 20127, Italy
    Recruiting
  • Alkermes Investigational Site
    Verona, 37134, Italy
    Recruiting
  • Alkermes Investigational Site
    Zwolle, 8025, Netherlands
    Recruiting
  • Alkermes Investigational Site
    Madrid, Madrid 28036, Spain
    Recruiting
  • Alkermes Investigational Site
    Barcelona, 08036, Spain
    Recruiting
  • Alkermes Investigational Site
    Madrid, 28043, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Jun 2030, 65 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jun 2028 → Jun 2030 and completion Jun 2028 → Jun 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartActual
Jan 27, 2025
Primary completionEst.
Jun 2030was Jun 2028
CompletionEst.
Jun 2030was Jun 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Alkermes Investigational Site · Dallas, United States
Oct 9, 2026
Primary completion
Jun 2028→Jun 2030
Oct 9, 2026
Study completion
Jun 2028→Jun 2030
Oct 9, 2026
Enrollment
256→786
Oct 9, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedWas eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1)
Oct 9, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameIncidence of Treatment-Emergent Adverse EventsUp to 100 Weeks → Up to 248 Weeks
Oct 9, 2026
Secondary outcomes
1 time frame changed, 2 added
What changed in the outcomes
  • AddedChange in weekly cataplexy rate (WCR)Time frame: Baseline up to week 240
  • AddedChange in Idiopathic Hypersomnia Severity Scale (IHSS)Time frame: Baseline up to week 240
  • Time frameChange in Epworth Sleepiness Scale (ESS)Baseline to 96 Weeks → Baseline to up to week 240
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added
    Show site
    • Alkermes Investigational Site · Dallas, United States
    Primary completion Jun 2028→Jun 2030
    Study completion Jun 2028→Jun 2030
    Enrollment 256→786
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedWas eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameIncidence of Treatment-Emergent Adverse EventsUp to 100 Weeks → Up to 248 Weeks
    Secondary outcomes 1 time frame changed, 2 added
    What changed in the outcomes
    • AddedChange in weekly cataplexy rate (WCR)Time frame: Baseline up to week 240
    • AddedChange in Idiopathic Hypersomnia Severity Scale (IHSS)Time frame: Baseline up to week 240
    • Time frameChange in Epworth Sleepiness Scale (ESS)Baseline to 96 Weeks → Baseline to up to week 240
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06767683
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Jan 27, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Director, Global Clinical Services
Contact
clinicaltrials@alkermes.com
888-235-8008 (US Only)
Director, Global Clinical Services
Contact
clinicaltrials@alkermes.com
571-599-2702 (Global)
Medical Director
study director · Alkermes, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alixorexton

Start the discussion